Tazarotene

他扎罗汀

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameTazarotene
Drug Alias Name他佐罗汀tazaroteno他紮罗汀tazarotenumFabior +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinoic acid receptor gamma agonistsRetinoic acid receptor alpha agonistsRetinoic acid receptor beta agonists
TargetsRetinoic acid receptor betaRetinoic acid receptor gammaRetinoic acid receptor alpha
Therapy Area/IndicationsPlaque psoriasisSolid tumoursPsoriasis +[9] 
Global Approved IndicationsPlaque psoriasisPsoriasisParapsoriasis +[4] 
Approved Indications in ChinaPlaque psoriasisAcne Vulgaris
Original Approved Country/TerritoryGermany
Original Approved Date1996/01/01
Country/TerritoryBelizeCanadaUnited States +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesAlmirall LlcAllergan PlcChongqing Huapont Pharmaceutical Co Ltd
Inactive CompaniesDana-Farber Cancer InstituteStiefel LaboratoriesG&W Laboratories Inc +[11] 
Active IndicationsPlaque psoriasisPsoriasisParapsoriasis +[4] 
Inactive IndicationsSolid tumoursHand-Foot SyndromeSkin Neoplasms +[5] 

Other Information

ATC CodeD05AX05
Related LinksWikipediaDrugBankKEGG